Multiple Myeloma

SWIFT-seq revolutionizes multiple myeloma diagnosis, offering a noninvasive blood test that enhances monitoring and risk assessment for patients.

CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression free at 5 years without maintenance.

Discover the latest advancements in multiple myeloma treatment, including new therapies and FDA approvals that enhance patient outcomes and survival rates.

Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission.

Sanofi's SAR446523 receives orphan drug designation for relapsed/refractory multiple myeloma, enhancing treatment options and patient outcomes.

Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma.

The advisory committee cited concerns around ocular toxicity and overall tolerability, raising serious questions about the drug's benefit-risk profile ahead of its scheduled Prescription Drug User Fee Act action date on July 23, 2025.

The National Comprehensive Cancer Network (NCCN) has released multiple myeloma guidelines version 2.2026 to include linvoseltamab as a preferred treatment for heavily pretreated patients, highlighting its intravenous formulation, dosing options, and streamlined Risk Evaluation and Mitigation Strategy program.

The data showed patients with relapsed or refractory multiple myeloma achieved a 73% overall response rate.

New data reveal isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.

The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.

CARTITUDE-1 trial reveals cilta-cel's potential in achieving long-term remission for relapsed/refractory multiple myeloma, sparking discussions on curative possibilities.

FDA removes REMS for CAR T-cell therapies, enhancing patient access while ensuring safety in cancer treatment.

The agent continues to show promising clinical benefit despite being pulled from the market in 2023.

Data from a phase 1b study showed significantly reduced toxicity compared with conventional oral dosing.

Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.

Bispecific therapies require clearer terminology to improve safety and communication.

Cilta-cel shows promise as a CAR T-cell therapy, offering long-term remission for patients with relapsed/refractory multiple myeloma without maintenance treatment.

The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases.

MRD testing transforms multiple myeloma treatment, guiding personalized strategies and improving patient outcomes through innovative testing methods.

Elranatamab shows promising efficacy and manageable safety in transplant-ineligible newly diagnosed multiple myeloma patients, highlighting its potential as a treatment option.

Daratumumab combined with VRd significantly improved outcomes in transplant-ineligible/transplant deferred patients with newly diagnosed multiple myeloma.

Physical activity significantly enhanced quality of life and reduced fatigue and depression in patients with newly diagnosed multiple myeloma.

The data are from the phase 2 iMMagine-1 study.

The agent demonstrated promising tolerability and manageable safety.

The salvage therapy led to an 80% overall response rate in patients with relapsed/refractory multiple myeloma.

Explore the latest advancements in treating transplant-ineligible multiple myeloma, highlighting new therapies and clinical trial outcomes for improved patient care.

A phase 1b study demonstrated that continuous subcutaneous infusion of low-dose lenalidomide in patients with relapsed or refractory (R/R) multiple myeloma achieved promising efficacy with significantly reduced hematologic toxicity compared to conventional oral dosing.

Erin Harrell, PharmD, offers insights about managing peripheral neuropathy in patients receiving bortezomib.

The multiple myeloma landscape is evolving, with bispecific T-cell engagers offering hope.